Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2441
{ "count": 24593, "next": "http://api.gregory-ms.com/articles/?format=api&page=2442", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2440", "results": [ { "article_id": 196, "title": "The effects of PDE inhibitors on multiple sclerosis: a review of in vitro and in vivo models", "summary": "<div><p>Curr Pharm Des. 2021 Mar 3. doi: 10.2174/1381612827666210303142356. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory and immune-mediated disease, whose current therapeutic means are mostly effective in the relapsing-remitting form of MS, where inflammation is still prominent, but fall short of preventing long term impairment. However, apart from inflammation-mediated demyelination, autoimmune mechanisms play a major role in MS pathophysiology, constituting a promising pharmacological target. Phosphodiesterase (PDE) inhibitors have been approved for clinical use in psoriasis and have undergone trials suggesting their neuroprotective effects, rendering them eligible as an option for accessory MS therapy.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: In this review, we discuss the potential role of PDE inhibitors as a complementary MS therapy.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: We conducted a literature search through which we screened and comparatively assessed papers on the effects of PDE inhibitor use, both in vitro and in animal models of MS, taking into account a number of inclusion and exclusion criteria.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: In vitro studies indicated that PDE inhibitors promote remyelination and axonal sustenance, while curbing inflammatory cell infiltration, hindering oligodendrocyte and neuronal loss and suppressing cytokine production. In vivo studies underlined that these agents alleviate symptoms and reduce disease scores in MS animal models.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: PDE inhibitors proved to be effective in addressing various aspects of MS pathogenesis both in vitro and in vivo models. Given the latest clinical trials proving that the PDE4 inhibitor Ibudilast exerts neuroprotective effects in patients with progressive MS, research on this field should be intensified and selective PDE4 inhibitors with enhanced safety features should be seriously considered as prospective complementary MS therapy.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33655851/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303135644&v=2.14.2\">33655851</a> | DOI:<a href=\"https://doi.org/10.2174/1381612827666210303142356\">10.2174/1381612827666210303142356</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33655851/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Bentham Science Publishers Ltd.", "container_title": "Current Pharmaceutical Design", "authors": [ { "author_id": 240760, "given_name": "Alexandra", "family_name": "Ainatzoglou", "ORCID": null, "country": null }, { "author_id": 240761, "given_name": "Eleni", "family_name": "Stamoula", "ORCID": null, "country": null }, { "author_id": 240762, "given_name": "Ioannis", "family_name": "Dardalas", "ORCID": null, "country": null }, { "author_id": 220311, "given_name": "Spyridon", "family_name": "Siafis", "ORCID": "http://orcid.org/0000-0001-8264-2039", "country": "DE" }, { "author_id": 194057, "given_name": "Georgios", "family_name": "Papazisis", "ORCID": "http://orcid.org/0000-0003-1641-9095", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T18:56:45Z", "noun_phrases": [ "The effects", "PDE inhibitors", "multiple sclerosis", "a review", "vivo models" ], "doi": "10.2174/1381612827666210303142356", "access": "restricted", "takeaways": " Phosphodiesterase (PDE) inhibitors have been approved for clinical use in psoriasis and have undergone trials suggesting their neuroprotective effects . In vitro studies indicated that PDE inhibitors promote remyelination and axonal sustenance, curbing inflammatory cell infiltration, hindering oligodendrocyte and neuronal loss and suppressing cytokine production .", "categories": [] }, { "article_id": 197, "title": "Change in Learning and Memory Partially Mediates Effects of Compensatory Cognitive Training on Self-Reported Cognitive Symptoms", "summary": "<div><p>J Head Trauma Rehabil. 2021 Feb 22. doi: 10.1097/HTR.0000000000000662. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: To examine associations among compensatory cognitive training (CCT), objective cognitive functioning, and self-reported cognitive symptoms. We examined whether change in objective cognitive functioning associated with participation in CCT at 10-week follow-up mediates change in self-reported cognitive symptoms associated with CCT at 15-week follow-up.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">SETTING: Three VA outpatient mental health clinics.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">PARTICIPANTS: Veterans with a history of mild traumatic brain injury who reported cognitive deficits.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">DESIGN: Randomized controlled trial post hoc causal mediation analysis.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">MAIN MEASURES: Self-reported cognitive symptoms were measured by the Prospective-Retrospective Memory Questionnaire and the Multiple Sclerosis Neuropsychological Screening Questionnaire. Objective cognitive functioning was measured using a battery of neuropsychological tests.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Improvement on the Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall test mediated the association between participation in CCT and decrease in the Prospective-Retrospective Memory Questionnaire total score. Improvement on the HVLT-R Total Recall and HVLT-R Delayed Recall tests both meditated the association between participation in CCT and decrease in the Multiple Sclerosis Neuropsychological Screening Questionnaire total score. No other measures of objective cognitive functioning were significant mediators.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: Patients' perceptions of cognitive symptom improvement due to CCT are partially mediated by learning and memory, though these subjective improvements occur regardless of other changes in objective cognitive functioning associated with CCT.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33656484/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303135644&v=2.14.2\">33656484</a> | DOI:<a href=\"https://doi.org/10.1097/HTR.0000000000000662\">10.1097/HTR.0000000000000662</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33656484/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Ovid Technologies (Wolters Kluwer Health)", "container_title": "Journal of Head Trauma Rehabilitation", "authors": [ { "author_id": 240797, "given_name": "Maya Elin", "family_name": "O'Neil", "ORCID": null, "country": null }, { "author_id": 240799, "given_name": "David", "family_name": "Cameron", "ORCID": null, "country": null }, { "author_id": 240801, "given_name": "Kate", "family_name": "Shirley", "ORCID": null, "country": null }, { "author_id": 240803, "given_name": "Emily", "family_name": "Sano", "ORCID": null, "country": null }, { "author_id": 240805, "given_name": "Elizabeth", "family_name": "Twamley", "ORCID": null, "country": null }, { "author_id": 240806, "given_name": "Rhonda", "family_name": "Williams", "ORCID": null, "country": null }, { "author_id": 240809, "given_name": "Aaron", "family_name": "Turner", "ORCID": null, "country": null }, { "author_id": 240810, "given_name": "Kathleen", "family_name": "Pagulayan", "ORCID": null, "country": null }, { "author_id": 240812, "given_name": "Mai", "family_name": "Roost", "ORCID": null, "country": null }, { "author_id": 240814, "given_name": "Amy", "family_name": "Jak", "ORCID": null, "country": null }, { "author_id": 240816, "given_name": "Daniel", "family_name": "Storzbach", "ORCID": null, "country": null }, { "author_id": 240818, "given_name": "Marilyn", "family_name": "Huckans", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T18:56:45Z", "noun_phrases": [ "Learning", "Memory Partially Mediates", "Effects", "Compensatory Cognitive Training", "Self-Reported Cognitive Symptoms" ], "doi": "10.1097/HTR.0000000000000662", "access": "restricted", "takeaways": " Veterans with a history of mild traumatic brain injury who reported cognitive deficits reported . Patients' perceptions of cognitive symptom improvement due to CCT are partially mediated by learning and memory . No other measures of objective cognitive functioning were significant mediators .", "categories": [ { "category_id": 18, "category_description": "Search terms: telerehabilitation, physical therapy, virtual reality, gamification, neurostimulation, cognitive training, spasticity, motor control.\n\nSuggested by Alejandro Carrabs", "category_name": "Physical therapy and Telerehabilitation", "category_slug": "physical-therapy-and-telerehabilitation", "category_terms": [ "telerehabilitation", "physical therapy", "virtual reality", "gamification", "neurostimulation", "cognitive training", "spasticity", "motor control" ], "article_count": 178 } ] }, { "article_id": 191, "title": "The Seaweed Diet in Prevention and Treatment of the Neurodegenerative Diseases", "summary": "<div><p>Mar Drugs. 2021 Feb 26;19(3):128. doi: 10.3390/md19030128.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Edible marine algae are rich in bioactive compounds and are, therefore, a source of bioavailable proteins, long chain polysaccharides that behave as low-calorie soluble fibers, metabolically necessary minerals, vitamins, polyunsaturated fatty acids, and antioxidants. Marine algae were used primarily as gelling agents and thickeners (phycocolloids) in food and pharmaceutical industries in the last century, but recent research has revealed their potential as a source of useful compounds for the pharmaceutical, medical, and cosmetic industries. The green, red, and brown algae have been shown to have useful therapeutic properties in the prevention and treatment of neurodegenerative diseases: Parkinson, Alzheimer's, and Multiple Sclerosis, and other chronic diseases. In this review are listed and described the main components of a suitable diet for patients with these diseases. In addition, compounds derived from macroalgae and their neurophysiological activities are described.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33652930/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303073644&v=2.14.2\">33652930</a> | DOI:<a href=\"https://doi.org/10.3390/md19030128\">10.3390/md19030128</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33652930/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-26T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "MDPI AG", "container_title": "Marine Drugs", "authors": [ { "author_id": 196047, "given_name": "Leonel", "family_name": "Pereira", "ORCID": "http://orcid.org/0000-0002-6819-0619", "country": "PT" }, { "author_id": 196048, "given_name": "Ana", "family_name": "Valado", "ORCID": "http://orcid.org/0000-0002-0157-6648", "country": "PT" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T12:36:46Z", "noun_phrases": [ "The Seaweed Diet", "Prevention", "Treatment", "the Neurodegenerative Diseases" ], "doi": "10.3390/md19030128", "access": "open", "takeaways": " The green, red, and brown algae have been shown to have useful therapeutic properties in the prevention and treatment of neurodegenerative diseases: Parkinson, Alzheimer's, and Multiple Sclerosis, and other chronic diseases .", "categories": [] }, { "article_id": 189, "title": "Brain Activation Changes While Walking in Adults with and without Neurological Disease: Systematic Review and Meta-Analysis of Functional Near-Infrared Spectroscopy Studies", "summary": "<div><p>Brain Sci. 2021 Feb 26;11(3):291. doi: 10.3390/brainsci11030291.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">(1) Functional near-infrared spectroscopy (fNIRS) provides a useful tool for monitoring brain activation changes while walking in adults with neurological disorders. When combined with dual task walking paradigms, fNIRS allows for changes in brain activation to be monitored when individuals concurrently attend to multiple tasks. However, differences in dual task paradigms, baseline, and coverage of cortical areas, presents uncertainty in the interpretation of the overarching findings. (2) Methods: By conducting a systematic review of 35 studies and meta-analysis of 75 effect sizes from 17 studies on adults with or without neurological disorders, we show that the performance of obstacle walking, serial subtraction and letter generation tasks while walking result in significant increases in brain activation in the prefrontal cortex relative to standing or walking baselines. (3) Results: Overall, we find that letter generation tasks have the largest brain activation effect sizes relative to walking, and that significant differences between dual task and single task gait are seen in persons with multiple sclerosis and stroke. (4) Conclusions: Older adults with neurological disease generally showed increased brain activation suggesting use of more attentional resources during dual task walking, which could lead to increased fall risk and mobility impairments. PROSPERO ID: 235228.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33652706/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303073644&v=2.14.2\">33652706</a> | DOI:<a href=\"https://doi.org/10.3390/brainsci11030291\">10.3390/brainsci11030291</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33652706/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-26T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "MDPI AG", "container_title": "Brain Sciences", "authors": [ { "author_id": 249950, "given_name": "Alka", "family_name": "Bishnoi", "ORCID": null, "country": null }, { "author_id": 167408, "given_name": "Roee", "family_name": "Holtzer", "ORCID": "http://orcid.org/0000-0001-6639-0724", "country": null }, { "author_id": 160048, "given_name": "Manuel E.", "family_name": "Hernandez", "ORCID": "http://orcid.org/0000-0002-3501-9508", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T12:36:46Z", "noun_phrases": [ "Brain Activation Changes", "Adults", "Neurological Disease", "Systematic Review", "Meta-Analysis", "Functional Near-Infrared Spectroscopy Studies" ], "doi": "10.3390/brainsci11030291", "access": "open", "takeaways": " Functional near-infrared spectroscopy (fNIRS) provides a useful tool for monitoring brain activation changes while walking in adults with neurological disorders . The performance of obstacle walking, serial subtraction and letter generation tasks while walking result in significant increases in brain activation in the prefrontal cortex relative to standing or walking baselines .", "categories": [] }, { "article_id": 186, "title": "Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis", "summary": "<div><p>Neurol Neuroimmunol Neuroinflamm. 2021 Mar 2;8(3):e975. doi: 10.1212/NXI.0000000000000975. Print 2021 May.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: Therapies targeting B cells have been used in the clinic for multiple sclerosis (MS). In patients with relapsing MS, anti-CD20 therapy often suppresses relapse activity; yet, their effect on disease progression has been disappointing. Most anti-CD20 therapeutic antibodies are type I, but within the unique microenvironment of the brain, type II antibodies may be more beneficial, as type II antibodies exhibit reduced complement-dependent cytotoxicity and they have an increased capacity to induce direct cell death that is independent of the host immune response.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: We compared the effect of type I with type II anti-CD20 therapy in a new rodent model of secondary progressive MS (SPMS), which recapitulates the principal histopathologic features of MS including meningeal B-cell aggregates. Focal MS-like lesions were induced by injecting heat-killed <i>Mycobacterium tuberculosis</i> into the piriform cortex of MOG-immunized mice. Groups of mice were treated with anti-CD20 antibodies (type I [rituxumab, 10 mg/kg] or type II [GA101, 10 mg/kg]) 4 weeks after lesion initiation, and outcomes were evaluated by immunohistochemistry.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Anti-CD20 therapy decreased the extent of glial activation, significantly decreased the number of B and T lymphocytes in the lesion, and resulted in disruption of the meningeal aggregates. Moreover, at the given dose, the type II anti-CD20 therapy was more efficacious than the type I and also protected against neuronal death.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: These results indicate that anti-CD20 may be an effective therapy for SPMS with B-cell aggregates and that the elimination of CD20<sup>+</sup> B cells alone is sufficient to cause disruption of aggregates in the brain.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33653962/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303073644&v=2.14.2\">33653962</a> | DOI:<a href=\"https://doi.org/10.1212/NXI.0000000000000975\">10.1212/NXI.0000000000000975</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33653962/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-02T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Ovid Technologies (Wolters Kluwer Health)", "container_title": "Neurology - Neuroimmunology Neuroinflammation", "authors": [ { "author_id": 193509, "given_name": "Jay", "family_name": "Roodselaar", "ORCID": "http://orcid.org/0000-0002-9321-7836", "country": null }, { "author_id": 196125, "given_name": "Yifan", "family_name": "Zhou", "ORCID": "http://orcid.org/0000-0002-3538-621X", "country": null }, { "author_id": 188960, "given_name": "David", "family_name": "Leppert", "ORCID": "http://orcid.org/0000-0001-6172-801X", "country": null }, { "author_id": 240732, "given_name": "Anja E.", "family_name": "Hauser", "ORCID": null, "country": null }, { "author_id": 240733, "given_name": "Eduard", "family_name": "Urich", "ORCID": null, "country": null }, { "author_id": 240734, "given_name": "Daniel C.", "family_name": "Anthony", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T12:36:46Z", "noun_phrases": [ "Anti-CD20 Disrupts Meningeal B-Cell Aggregates", "a Model", "Secondary Progressive Multiple Sclerosis" ], "doi": "10.1212/NXI.0000000000000975", "access": "open", "takeaways": " Therapies targeting B cells have been used in the clinic for multiple sclerosis . In patients with relapsing MS, anti-CD20 therapy often suppresses relapse activity . Yet, their effect on disease progression has been disappointing .", "categories": [] }, { "article_id": 188, "title": "Multiple Sclerosis Relapse Presenting As Sensorineural Hearing Loss", "summary": "<div><p>Neurology. 2021 Mar 2:10.1212/WNL.0000000000011796. doi: 10.1212/WNL.0000000000011796. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33653899/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303073644&v=2.14.2\">33653899</a> | DOI:<a href=\"https://doi.org/10.1212/WNL.0000000000011796\">10.1212/WNL.0000000000011796</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33653899/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-04-19T23:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Ovid Technologies (Wolters Kluwer Health)", "container_title": "Neurology", "authors": [ { "author_id": 240750, "given_name": "Parth", "family_name": "Bansal", "ORCID": null, "country": null }, { "author_id": 240751, "given_name": "Birinder S.", "family_name": "Paul", "ORCID": null, "country": null }, { "author_id": 240752, "given_name": "Gagandeep", "family_name": "Singh", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T12:36:46Z", "noun_phrases": [ "Sensorineural Hearing Loss" ], "doi": "10.1212/WNL.0000000000011796", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 190, "title": "Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis", "summary": "<div><p>Neurology. 2021 Mar 2:10.1212/WNL.0000000000011788. doi: 10.1212/WNL.0000000000011788. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: To evaluate whether a retinal spectral-domain optical coherence tomography (SD-OCT) assessment at baseline is associated with long-term disability worsening in people with multiple sclerosis (PwMS), we performed SD-OCT and Expanded Disability Status Scale (EDSS) assessments among 132 PwMS at baseline and at a median of 10 years later.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: In this prospective, longitudinal study, participants underwent SD-OCT, EDSS, and visual acuity (VA) assessments at baseline and at follow-up. Statistical analyses were performed using generalized linear regression models, adjusted for age, sex, race, MS subtype, and baseline disability. We defined clinically meaningful EDSS worsening as an increase of ≥2.0 if baseline EDSS score was <6.0, or an increase of ≥1.0 if baseline EDSS score was ≥6.0.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: 132 PwMS (mean age: 43 years; n=106 patients with relapsing remitting MS) were included in analyses. Median duration of follow-up was 10.4 years. In multivariable models excluding eyes with prior optic neuritis, relative to patients with an average baseline ganglion cell+inner plexiform layer (GCIPL) thickness ≥70µm (the mean GCIPL thickness of all eyes at baseline), an average baseline GCIPL thickness <70µm was associated with a 4-fold increased odds of meaningful EDSS worsening (adjusted odds ratio: 3.97; 95% CI: 1.24-12.70; p=0.02), and an almost 3-fold increased odds of low-contrast VA worsening (adjusted odds ratio: 2.93; 95% CI: 1.40-6.13; p=0.04).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: Lower baseline GCIPL thickness on SD-OCT is independently associated with long-term disability worsening in MS. Accordingly, SD-OCT at a single time-point may help to guide therapeutic decision making among individual PwMS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that lower baseline GCIPL thickness on SD-OCT is independently associated with long-term disability worsening in MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33653904/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303073644&v=2.14.2\">33653904</a> | DOI:<a href=\"https://doi.org/10.1212/WNL.0000000000011788\">10.1212/WNL.0000000000011788</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33653904/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-04-19T23:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Ovid Technologies (Wolters Kluwer Health)", "container_title": "Neurology", "authors": [ { "author_id": 198140, "given_name": "Jeffrey", "family_name": "Lambe", "ORCID": "http://orcid.org/0000-0002-3306-0988", "country": null }, { "author_id": 147739, "given_name": "Kathryn C.", "family_name": "Fitzgerald", "ORCID": "http://orcid.org/0000-0003-3137-0322", "country": null }, { "author_id": 164792, "given_name": "Olwen C.", "family_name": "Murphy", "ORCID": "http://orcid.org/0000-0001-7880-8948", "country": null }, { "author_id": 172330, "given_name": "Angeliki G", "family_name": "Filippatou", "ORCID": "http://orcid.org/0000-0003-0419-233X", "country": null }, { "author_id": 164484, "given_name": "Elias S", "family_name": "Sotirchos", "ORCID": "http://orcid.org/0000-0002-8812-1637", "country": "US" }, { "author_id": 198779, "given_name": "Grigorios", "family_name": "Kalaitzidis", "ORCID": "http://orcid.org/0000-0001-7680-3609", "country": null }, { "author_id": 172329, "given_name": "Eleni S", "family_name": "Vasileiou", "ORCID": "http://orcid.org/0000-0002-8639-8405", "country": null }, { "author_id": 240735, "given_name": "Nicole", "family_name": "Pellegrini", "ORCID": null, "country": null }, { "author_id": 240736, "given_name": "Esther", "family_name": "Ogbuokiri", "ORCID": null, "country": null }, { "author_id": 240737, "given_name": "Brandon", "family_name": "Toliver", "ORCID": null, "country": null }, { "author_id": 240738, "given_name": "Nicholas J.", "family_name": "Luciano", "ORCID": null, "country": null }, { "author_id": 240739, "given_name": "Simidele", "family_name": "Davis", "ORCID": null, "country": null }, { "author_id": 240740, "given_name": "Nicholas", "family_name": "Fioravante", "ORCID": null, "country": null }, { "author_id": 240741, "given_name": "Ohemaa", "family_name": "Kwakyi", "ORCID": null, "country": null }, { "author_id": 240742, "given_name": "Hunter", "family_name": "Risher", "ORCID": null, "country": null }, { "author_id": 240743, "given_name": "Ciprian M.", "family_name": "Crainiceanu", "ORCID": null, "country": null }, { "author_id": 198143, "given_name": "Jerry L.", "family_name": "Prince", "ORCID": "http://orcid.org/0000-0002-6553-0876", "country": "US" }, { "author_id": 165068, "given_name": "Scott D.", "family_name": "Newsome", "ORCID": "http://orcid.org/0000-0002-5284-4681", "country": null }, { "author_id": 218182, "given_name": "Ellen M.", "family_name": "Mowry", "ORCID": "http://orcid.org/0000-0003-0623-5188", "country": null }, { "author_id": 172340, "given_name": "Shiv", "family_name": "Saidha", "ORCID": "http://orcid.org/0000-0001-6387-0714", "country": null }, { "author_id": 150310, "given_name": "Peter A.", "family_name": "Calabresi", "ORCID": "http://orcid.org/0000-0002-7776-6472", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T12:36:46Z", "noun_phrases": [ "Association", "Spectral-Domain", "OCT", "Long-term Disability Worsening", "Multiple Sclerosis" ], "doi": "10.1212/WNL.0000000000011788", "access": "open", "takeaways": " Retinal spectral-domain optical coherence tomography (SD-OCT) assessment at baseline is associated with long-term disability worsening in people with multiple sclerosis (PwMS)", "categories": [] }, { "article_id": 185, "title": "Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation", "summary": "<div><p>Nat Rev Neurosci. 2021 Mar 2. doi: 10.1038/s41583-021-00431-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP43; also known as TARDBP or TDP-43) is a key pathological feature of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP43 typically resides in the nucleus but can shuttle between the nucleus and the cytoplasm to exert its multiple functions, which include regulation of the splicing, trafficking and stabilization of RNA. Cytoplasmic mislocalization and nuclear loss of TDP43 have both been associated with ALS and FTD, suggesting that calibrated levels and correct localization of TDP43 - achieved through an autoregulatory loop and tightly controlled nucleocytoplasmic transport - safeguard its normal function. Furthermore, TDP43 can undergo phase transitions, including its dispersion into liquid droplets and its accumulation into irreversible cytoplasmic aggregates. Thus, autoregulation, nucleocytoplasmic transport and phase transition are all part of an intrinsic control system regulating the physiological levels and localization of TDP43, and together are essential for the cellular homeostasis that is affected in neurodegenerative disease.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33654312/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303073644&v=2.14.2\">33654312</a> | DOI:<a href=\"https://doi.org/10.1038/s41583-021-00431-1\">10.1038/s41583-021-00431-1</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33654312/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-04T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Nature Reviews Neuroscience", "authors": [ { "author_id": 233318, "given_name": "Paraskevi", "family_name": "Tziortzouda", "ORCID": "http://orcid.org/0000-0002-6969-8158", "country": null }, { "author_id": 233319, "given_name": "Ludo", "family_name": "Van Den Bosch", "ORCID": "http://orcid.org/0000-0003-0104-4067", "country": null }, { "author_id": 233320, "given_name": "Frank", "family_name": "Hirth", "ORCID": "http://orcid.org/0000-0001-8581-9450", "country": "GB" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T12:36:46Z", "noun_phrases": [ "Triad", "TDP43 control", "neurodegeneration", "autoregulation", "localization", "aggregation" ], "doi": "10.1038/s41583-021-00431-1", "access": "open", "takeaways": " Cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP43) is a key pathological feature of several neurodegenerative diseases, including ALS and FTD . TDP43 typically resides in the nucleus but can shuttle between the nucleus and the cytoplasma to exert its multiple functions, including regulation of splicing, trafficking and stabilization of RNA .", "categories": [] }, { "article_id": 187, "title": "Seeing the Finish Line: Can Baseline OCT Values Predict Long-Term Disability and Therapeutic Management in Multiple Sclerosis?", "summary": "<div><p>Neurology. 2021 Mar 2:10.1212/WNL.0000000000011793. doi: 10.1212/WNL.0000000000011793. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33653903/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303073644&v=2.14.2\">33653903</a> | DOI:<a href=\"https://doi.org/10.1212/WNL.0000000000011793\">10.1212/WNL.0000000000011793</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33653903/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-04-19T23:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Ovid Technologies (Wolters Kluwer Health)", "container_title": "Neurology", "authors": [ { "author_id": 150343, "given_name": "Pablo", "family_name": "Villoslada", "ORCID": "http://orcid.org/0000-0002-8735-6119", "country": null }, { "author_id": 165284, "given_name": "Steven L.", "family_name": "Galetta", "ORCID": "http://orcid.org/0000-0003-3781-7324", "country": null }, { "author_id": 150342, "given_name": "Ahmed", "family_name": "Toosy", "ORCID": "http://orcid.org/0000-0002-4441-3750", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T12:36:46Z", "noun_phrases": [ "the Finish Line", "Long-Term Disability and Therapeutic Management", "Multiple Sclerosis" ], "doi": "10.1212/WNL.0000000000011793", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 184, "title": "Risk of Psychiatric Disorders in Multiple Sclerosis: A Nationwide Cohort Study in an Asian Population", "summary": "<div><p>Neuropsychiatr Dis Treat. 2021 Feb 22;17:587-604. doi: 10.2147/NDT.S268360. eCollection 2021.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Multiple sclerosis (MS) is a demyelinating disease that can damage neurons in the brain and spinal cord and is associated with several psychiatric disorders. However, few studies have evaluated the risk of psychiatric disorders in patients with MS by using a nationwide database. This study investigated the association between MS and the risk of psychiatric disorders.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Using data from the Taiwan National Health Insurance Research Database from 2000 to 2015, we identified 1066 patients with MS. After adjustment for confounding factors, Fine and Gray's competing risk model was used to compare the risk of psychiatric disorders during 15 years of follow-up.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Of the patients with MS, 531 (4622.86 per 10<sup>5</sup> person years) developed psychiatric disorders; by contrast, 891 of the 3198 controls (2485.31 per 10<sup>5</sup> person years) developed psychiatric disorders. Fine and Gray's competing risk model revealed an adjusted hazard ratio (HR) of 5.044 (95% confidence interval = 4.448-5.870, <i>p</i> < 0.001) after adjustment for all the covariates. MS was associated with depression, anxiety, bipolar disorder, sleep disorders, schizophrenia, schizophreniform disorder, and other psychotic disorders (adjusted HR: 12.464, 4.650, 6.987, 9.103, 2.552, 2.600, 2.441, and 2.574, respectively; all p < 0.001). Some disease-modifying drugs were associated with a lower risk of anxiety or depression.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: Patients with MS were determined to have a higher risk of developing a wide range of psychiatric disorders.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33654401/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303073644&v=2.14.2\">33654401</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7910105/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303073644&v=2.14.2\">PMC7910105</a> | DOI:<a href=\"https://doi.org/10.2147/NDT.S268360\">10.2147/NDT.S268360</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33654401/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-22T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Informa UK Limited", "container_title": "Neuropsychiatric Disease and Treatment", "authors": [ { "author_id": 240688, "given_name": "Yao-Ching", "family_name": "Huang", "ORCID": null, "country": null }, { "author_id": 240689, "given_name": "Wu-Chien", "family_name": "Chien", "ORCID": null, "country": null }, { "author_id": 171544, "given_name": "Chi-Hsiang", "family_name": "Chung", "ORCID": "http://orcid.org/0000-0002-4576-9900", "country": null }, { "author_id": 240690, "given_name": "Hsin-An", "family_name": "Chang", "ORCID": null, "country": null }, { "author_id": 240691, "given_name": "Yu-Chen", "family_name": "Kao", "ORCID": null, "country": null }, { "author_id": 240692, "given_name": "Fang-Jung", "family_name": "Wan", "ORCID": null, "country": null }, { "author_id": 171548, "given_name": "Shi-Hao", "family_name": "Huang", "ORCID": "http://orcid.org/0000-0002-9304-3418", "country": null }, { "author_id": 171549, "given_name": "Ren-Jei", "family_name": "Chung", "ORCID": "http://orcid.org/0000-0002-0655-3680", "country": "TW" }, { "author_id": 171550, "given_name": "Richard S", "family_name": "Wang", "ORCID": "http://orcid.org/0000-0002-4317-2940", "country": null }, { "author_id": 171551, "given_name": "Bing-Long", "family_name": "Wang", "ORCID": "http://orcid.org/0000-0001-9910-9804", "country": null }, { "author_id": 171552, "given_name": "Nian-Sheng", "family_name": "Tzeng", "ORCID": "http://orcid.org/0000-0001-5881-7089", "country": null }, { "author_id": 240693, "given_name": "Chien-An", "family_name": "Sun", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T12:36:46Z", "noun_phrases": [ "Risk", "Psychiatric Disorders", "Multiple Sclerosis", "A Nationwide Cohort Study", "an Asian Population" ], "doi": "10.2147/NDT.S268360", "access": "open", "takeaways": " Multiple sclerosis (MS) is a demyelinating disease that can damage neurons in the brain and spinal cord and is associated with several psychiatric disorders . Few studies have evaluated the risk of psychiatric disorders in patients with MS by using a nationwide database .", "categories": [] } ] }